Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

Journal of Thoracic Oncology, Journal Year: 2022, Volume and Issue: 17(12), P. 1335 - 1354

Published: Sept. 29, 2022

Language: Английский

---

Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, large-sample informatics study

International Journal of Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: April 23, 2024

Neoadjuvant and adjuvant immunotherapies for cancer have evolved through a series of remarkable critical research advances; however, addressing their similarities differences is imperative in clinical practice. Therefore, this study aimed to examine from the perspective informatics analysis.

Language: Английский

---

Therapeutic Antibodies in Medicine

Molecules, Journal Year: 2023, Volume and Issue: 28(18), P. 6438 - 6438

Published: Sept. 5, 2023

Antibody engineering has developed into a wide-reaching field, impacting multitude of industries, most notably healthcare and diagnostics. The seminal work on developing the first monoclonal antibody four decades ago witnessed exponential growth in last 10–15 years, where regulators have approved antibodies as therapeutics for several diagnostic applications, including remarkable attention it garnered during pandemic. In recent become fastest-growing class biological drugs treatment wide range diseases, from cancer to autoimmune conditions. This review discusses field therapeutic stands today. It summarizes outlines clinical relevance application treating landscape diseases different disciplines medicine. nomenclature, various approaches therapies, evolution therapeutics. also risk profile adverse immune reactions associated with sheds light future applications perspectives drug discovery.

Language: Английский

---

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 28, 2024

Background Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide. Lymphocytes are primary executors immune system and play essential roles in tumorigenesis development. We investigated dynamic changes peripheral blood lymphocyte subsets to predict efficacy chemotherapy or combination immunotherapy NSCLC. Methods This retrospective study collected data from 81 patients with NSCLC who received treatments at First Affiliated Hospital Zhengzhou University May 2021 2023. Patients were divided into response non-response groups, first-line multiline groups. analyzed absolute counts each subset baseline after treatment cycle. Within-group between-group differences using paired Wilcoxon signed-rank Mann-Whitney U tests, respectively. The ability was receiver operating characteristic curve logistic regression. Results group significantly increased first cycle immunotherapy, whereas those showed persistent decreases. Ratios able early. Combination could increase compared alone. In addition, receiving for time mainly presented elevated levels, continuous reductions. Conclusion Dynamic surveillance reflect a more actual status protected levels rapid decrease undergoing prone lymphopenia than treatment. provides reference early prediction clinical tumor timely improvement status.

Language: Английский

---

Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial

Targeted Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

Language: Английский

---

Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB–IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years

Anti-Cancer Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

This study aimed to evaluate the efficacy and safety of sintilimab combined with oral vinorelbine in newly diagnosed patients stage IIIb IV nonsmall cell lung cancer (NSCLC) who had an Eastern Cooperative Oncology Group performance status (PS) 2 or over 75 years age during initial treatment. prospective single-center single-arm enrolled histologically confirmed NSCLC. Eligible were administered vinorelbine. The primary endpoint was progression-free survival (PFS), secondary endpoints included objective response rate (ORR) disease control (DCR). Furthermore, this assessed indicators treatment safety. From September 2020 December 2023, 60 eligible Respiratory Department Shanxi Cancer Hospital. Following treatment, PFS 9.1 months, ORR DCR 39.6 63.79%, respectively. In addition, there a reduction blood tumor marker levels enhanced immune function. Adverse reactions relatively low incidence primarily consisted grade 1–2 cases. Sintilimab plus showed promising as first-line strategy for NSCLC PS elderly patients. It also optimizes function

Language: Английский

---

Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study

Thoracic Cancer, Journal Year: 2025, Volume and Issue: 16(6)

Published: March 1, 2025

ABSTRACT Background This study explored the safety and efficacy of combining radiotherapy with sintilimab in non‐small cell lung cancer (NSCLC) patients who have progressed after first or second‐line therapy. Methods In this multicenter, single‐arm trial, NSCLC had therapy were enrolled. Participants received hypofractionated stereotactic body (SBRT) (requiring a single‐site biological dose more than 30 Gy planned to reach Gy) followed by every 3 weeks until disease progression unacceptable toxicity occurred. Results From March 1, 2019, July 27, 2023, 14 enrolled across two centers. The cohort included 64.3% males 35.7% females, median age 67 years (range 57–73 years). All participants completed radiation at least one cycle sintilimab. overall response rate (ORR) was 21.4% (3/14) control (DCR) 71.4% (10/14). absent (ARR) 14.3% (2/14). PFS 4.17 months (95% CI: 1.15–8.69 months), 6‐month 42.9%. OS 16.17 11.69–20.64 months). Overall, 10 (71.4%) experienced treatment‐emergent adverse event (TEAE). Grade events case each immune‐related myocarditis, thrombocytopenia, checkpoint inhibitor pneumonitis (CIP). Four (28.6%) (irAEs) including skin rash pruritus (2/14, grade 1), myocarditis (1/14, 3), CIP 3). Conclusions Radiotherapy combined for first‐or showed promising outcomes.

Language: Английский

---

Pneumatosis intestinalis post steroid use in a patient with immune-related adverse events: Case report, literature review and FAERS analysis

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: March 14, 2023

Introduction: The accurate diagnosis of pneumatosis intestinalis (PI) is increasing despite patients' limited identification etiologic factors. Recently a patient with lung squamous carcinoma who developed following methylprednisolone administration for immune-related adverse events was treated at our hospital. Subsequent literature review and an analysis the FDA Adverse Event Reporting System (FAERS) database enabled additional cases intestinalis. Methods: A MEDLINE/PubMed Web Science Core Collection databases using standard search terms to identify published immune checkpoint inhibitors (ICIs) or steroids causing were performed. separate retrospective pharmacovigilance study FAERS extraction unpublished between first quarter 2005 third 2022. Disproportionality Bayesian analyses performed signal detection in reported odds ratios, proportional reporting information components, empirical geometric means. Results: Ten case reports steroid-related retrieved from six studies. implicated drug therapies included pre-treatment before chemotherapy, combination therapy cytotoxic agents steroids, monotherapy steroids. In study, 1,272 incidentally reported. detected five kinds implied positive correlation drugs events. Conclusion: Steroids might be factors current Reports supporting role suspected can found database. Even so, as documented FAERS, inhibitors-induced should not excluded.

Language: Английский

---

Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 29, 2024

Brain metastatic cancer poses a significant clinical challenge, with limited treatment options and poor prognosis for patients. In recent years, immunotherapy has emerged as promising strategy addressing brain metastases, offering distinct advantages over conventional treatments. This review explores the evolving landscape of tumor in context cancer, focusing on intricate interplay between microenvironment (TME) immunotherapeutic approaches. By elucidating complex interactions within TME, including role immune cells, cytokines, extracellular matrix components, this highlights potential to reshape paradigm metastases. Leveraging checkpoint inhibitors, cellular immunotherapies, personalized strategies, holds promise overcoming challenges posed by blood-brain barrier immunosuppressive Through comprehensive analysis current research findings future directions, underscores transformative impact management new insights opportunities precise therapeutic interventions.

Language: Английский

---

Late‑onset immune checkpoint inhibitor‑related pneumonitis after cessation of sintilimab: A case report and literature review

Experimental and Therapeutic Medicine, Journal Year: 2023, Volume and Issue: 25(2)

Published: Jan. 3, 2023

Immune‑related adverse events following treatment with immune checkpoint inhibitors (ICIs) can occur at any time during therapy, onset occurring most frequently the first 3 months of treatment. However, they rarely after cessation. An awareness delayed immune‑related termination immunotherapy is paramount for optimal tumour management. The present study reports a case 69‑year‑old male patient right lung adenocarcinoma. He suffered from psoriasis ~40 years and was suspected developing inhibitor‑related pneumonitis (CIP) 6 cessation anti‑programmed cell death‑1 receptor antibody sintilimab. is, to best our knowledge, late‑onset CIP Subsequently, report also reviews previously reported cases ICI highlights finding that develop, although reported, or even immunotherapy. Therefore, should always be considered as one possibilities addressed accordingly once pulmonary infection ruled out. Careful monitoring, timely diagnosis administration corticosteroids are essential in controlling this condition, particularly patients pre‑existing autoimmune diseases.

Language: Английский

---